Skip to main content

Table 2 Pulmonary function and 6-Minute-walk-distance characteristics of 10 patients with lymphangioleiomyomatosis

From: Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?

Pat. ID

FEV1(l/% pred.)

FVC (l/% pred.)

 

Baseline

3 months

p

6 months

p

baseline

3 months

p

6 months

p

1

1.79

62.0

1.39

49.0

 

2.22

77.6

 

2.65

77.4

2.75

81.4

 

3.17

93.2

 

2

1.51

44.8

1.89

56.1

 

1.88

55.3

 

3.02

78.3

3.27

84.8

 

3.26

84.1

 

3

1.69

44.3

1.86

48.7

 

1.98

51.9

 

2.90

66.1

2.99

67.3

 

3.12

71.4

 

4

1.39

43.7

1.84

58.4

 

2.03

64.4

 

2.58

71.7

3.06

85.5

 

3.63

99.3

 

5

0.34

12.3

0.53

19.1

 

0.64

23.3

 

0.78

24.9

1.58

49.6

 

1.54

48.1

 

6

1.00

29.8

1.35

41.1

 

1.41

42.9

 

2.86

74.1

2.91

76.3

 

3.56

93.3

 

7

0.93

34.4

1.22

45.1

 

1.11

41.3

 

3.17

99.0

2.99

94.2

 

2.99

94.2

 

8

0.85

25.8

1.03

31.3

 

1.05

31.9

 

2.38

63.4

3.35

89.1

 

2.54

67.2

 

9

0.95

27.6

1.22

41.6

 

1.30

44.4

 

2.98

88.5

2.94

86.4

 

3.18

94.2

 

10

0.49

22.4

1.03

47.0

 

1.08

48.9

 

1.40

52.3

2.48

90.6

 

2.61

95.5

 

Mean ± SEM

1.12 ± 0.15

36.1 ± 4.5

1.34 ± 0.14

44.0 ± 3.7

0.024

1.47 ± 0.17

48.1 ± 4.9

0.001

2.47 ± 0.25

69.2 ± 6.5

2.83 ± 0.16

80.2 ± 4.2

0.031

2.96 ± 0.19

83.9 ± 5.25

0.006